

ondine



For Immediate Release

Ondine's Periowave™ Photodisinfection System Showcased at Pacific Dental Conference in Vancouver BC

Vancouver, Canada – March 7, 2008 - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP; the "Company"), a medical technology company developing photodisinfection based products, today announced that its Periowave™ Photodisinfection System for the treatment of periodontal diseases will be showcased at the Pacific Dental Conference (Booth #2020) in Vancouver BC on March 6 - 8th, 2008.

Dr. Veronique Benhamou, DDS, a Periodontist and Director, Division of Periodontics, and Associate Professor at McGill University, Montreal Quebec will be speaking about Periowave™ and Photodisinfection today. Dr. Benhamou's presentation is titled "Photodisinfection – The Future of Periodontal Therapy".

"We are very pleased to have Dr. Benhamou, a prominent Canadian clinician, present Photodisinfection and her experience with Periowave™ in the clinics at McGill University at this leading Canadian dental conference," stated Carolyn Cross, Ondine's President & CEO. "With over 10,000 patients treated with Periowave™, clinicians across Canada and Europe are reporting that they are seeing exceptional results when treating periodontitis, peri-implantitis and other conditions with Periowave™."

Additional information on the Pacific Dental Conference can be found at www.pdconf.com.

About Periodontal Disease

Periodontitis (gum disease) is a common human affliction, affecting one third of all adults, and over half of the population over the age of 50. Periodontitis results in gum tissue detachment, bleeding gums, oral malodour, bone and tooth loss as well as other complications. The standard of care for treating periodontal disease is Scaling and Root Planing ("SRP"), or gum surgery, or both. SRP is the sub-gingival removal of plaque biofilm adhering to the root surfaces. Periodontitis is associated with a host of other serious conditions including heart disease, stroke, premature births and diabetes.

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is headquartered in Vancouver, British Columbia, Canada, with a

research laboratory in Bothell, Washington, USA, and an international office in St. Michael, Barbados. For additional information, please visit the Company's website at: www.ondinebiopharma.com.

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.

The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For further information please contact:

Carolyn Cross
President and
Chief Executive Officer
Ondine Biopharma Corporation
(604) 669-0555
ccross@ondinebiopharma.com

Christina Bessant
Investor Relations
The Equicom Group Inc.
(416) 815-0700 ext. 269
cbessant@equicomgroup.com

Irma Gomez-Dib
Media & Investors Relations
FD International
(212) 850-5761
Irma.gomez-dib@fd.com

Canaccord Adams Ltd
Nominated Adviser & Broker
Neil Johnson /
Ryan Gaffney
+4420 7050 6500